13F Holdings
中文EN

ISPC iSpecimen Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1558569 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-92.1%
TTM net income YoY-12.0%
TTM EPS YoY173.0%
Revenue 3-yr CAGR-64.1%
Net income 3-yr CAGR—

Margins

Gross margin-98.0%
Operating margin-2,020.0%
Net margin-2,449.0%
FCF margin—
EBITDA margin-1,899.3%

Returns

ROE-968.5%
ROA-170.1%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets76.5%
Debt / equity0.00x
Current ratio0.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.61x
Accruals ratio-65.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.93M$9.29M$9.93M$10.40M$11.14M
Cost of revenue$1.71M$5.11M$4.77M$4.76M$5.25M
Gross profit$215,665$4.18M$5.16M$5.65M$5.89M
R&D expense—$1.49M$1.62M$1.47M$879,243
SG&A expense$3.47M$6.07M$5.94M$6.93M$5.61M
Operating income-$8.98M-$12.73M-$11.17M-$10.19M-$5.93M
Interest expense$1,949$173,771$16,001$238,963$2.10M
Income tax———$0$0
Net income-$10.49M-$12.50M-$11.10M-$10.25M-$8.96M
EBITDA-$7.25M-$10.43M-$9.05M-$10.16M-$5.88M
EPS (basic)-2.28-17.58-24.55-1.16-2.09
EPS (diluted)-2.28-17.58-24.55-1.16-2.09
Weighted avg. shares (diluted)4.60M710,852452,0678.84M4.29M
Balance sheet
Cash & equivalents$6.88M$1.88M$2.34M$15.31M$27.74M
Short-term investments——$2.66M$0—
Receivables$48,298$1.44M$728,388$1.60M$3.00M
Inventory—$45,110———
Current assets$6.95M$3.59M$8.24M$19.68M$32.95M
PP&E, net$25,543$93,563$127,787$225,852$32,781
Total assets$9.53M$9.35M$15.82M$24.62M$35.72M
Current liabilities$6.23M$5.77M$6.05M$4.28M$2.51M
Long-term debt————$3.42M
Total debt————$3.42M
Total liabilities$6.44M$6.04M$6.08M$4.31M$5.93M
Shareholders' equity$3.09M$3.31M$9.74M$20.31M$29.79M
Net debt————-$24.32M
Shares outstanding211,9761.70M454,1698.93M8.73M
Cash flow statement
Operating cash flow-$4.24M-$8.26M-$5.81M-$5.82M-$10.67M
Capital expenditure$454$31,546$19,478$215,504$2,550
Free cash flow-$4.24M-$8.30M-$5.83M-$6.03M-$10.67M
Investing cash flow-$1.00M$1.98M-$7.23M-$3.19M-$1.04M
Financing cash flow$10.24M$5.82M$70,889-$3.42M$38.75M
Depreciation & amortization$1.73M$2.29M$2.12M$22,433$45,358
Stock-based compensation$21,266$249,675$459,666$678,613$622,064

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.